HomeATHA • NASDAQ
add
Athira Pharma Inc
Previous close
$0.38
Day range
$0.35 - $0.38
Year range
$0.22 - $0.83
Market cap
14.28M USD
Avg Volume
129.16K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.29M | -73.99% |
Net income | -6.97M | 74.06% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -7.05M | 74.63% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 29.82M | -67.50% |
Total assets | 35.54M | -68.05% |
Total liabilities | 3.56M | -87.25% |
Total equity | 31.99M | — |
Shares outstanding | 39.44M | — |
Price to book | 0.47 | — |
Return on assets | -46.11% | — |
Return on capital | -51.02% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -6.97M | 74.06% |
Cash from operations | -7.00M | 68.66% |
Cash from investing | 441.00K | -98.34% |
Cash from financing | 24.00K | -83.78% |
Net change in cash | -6.53M | -249.18% |
Free cash flow | -4.45M | 78.99% |
About
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Founded
2011
Headquarters
Website
Employees
26
